MED — Medifast, Inc.

Summary of Medifast, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $76 million, down 34.3% year-over-year, marking a slight sequential growth for the first time in three years.
• Net Loss: $2.1 million, or $0.19 per share, compared to a net loss of $800,000, or $0.07 per share, in Q1 2025.
• Active Earning Coaches: Approximately 14,000, a decline of 44.9% from the previous year.
• Average Revenue per Active Coach: Increased by 19.2% year-over-year to $5,432, indicating improved coach productivity.
• Gross Profit Margin: 68.1%, down from 72.8% in the previous year, primarily due to lower sales volumes.
• SG&A Expenses: Decreased by 35.6% year-over-year to $55.1 million, aided by a reduction in coach compensation and marketing expenses.

2. Strategic Updates and Business Highlights

• Medifast is transitioning to focus on the metabolic health market, responding to the rise of GLP-1 medications affecting traditional weight loss.
• The company has implemented a new foundational strategy termed "3.0," aimed at enhancing clinical and scientific foundations and aligning costs with market realities, projecting over $30 million in future savings.
• Coach productivity has improved, with a 19% year-over-year increase, indicating higher engagement and effectiveness in acquiring new clients.
• A new comprehensive metabolic health system is set to launch in July 2026, featuring products with clinically studied ingredients and a structured three-phase approach (reset, refine, renew) to support clients' metabolic health journeys.

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: Expected to range from $60 million to $80 million, with a loss per share between $0.50 and $1.00.
• Full-Year 2026 Revenue Guidance: Projected between $270 million and $300 million, with a loss per share between $1.05 and $2.75.
• Anticipation of returning to profitability starting in Q4 2026, coinciding with the launch of the new product line, with continued improvements expected into 2027.

4. Bad News, Challenges, or Points of Concern

• The number of active earning coaches has significantly declined, which poses a challenge for future growth.
• The traditional weight loss market is being disrupted by the rapid adoption of GLP-1 medications, which could continue to impact Medifast's business model.
• Despite improvements in coach productivity, there is a risk that revenue growth may lag behind these metrics, as historically observed.

5. Notable Q&A Insights

• Management emphasized the importance of coach productivity as a leading indicator for future growth, with expectations that improved productivity will eventually lead to an increase in the number of active coaches.
• The company is focusing on messaging around metabolic health, differentiating itself by emphasizing the quality of weight loss (e.g., reduction of visceral fat) rather than just weight loss metrics.
• There is optimism regarding the referral program, which is driving higher acquisition rates for coaches involved in it.
• CEO Daniel R. Chard announced his planned departure effective June 1, 2026, after nearly ten years, while expressing confidence in the leadership transition to Nicholas M. Johnson.

This summary encapsulates the key takeaways from Medifast's Q1 2026 earnings call, highlighting both the progress made and the challenges ahead as the company navigates a changing market landscape.